Neuroimaging and mechanisms of drug abuse: Interface of molecular imaging and molecular genetics

Neuroimaging Clinics of North America

Volumn 13, Issue 4, 2003, Pages 833-849

  Ernst, Monique ^a   Kimes, Alane S ^b   Jazbec, Sandra ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; COCAINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DOPAMINE RECEPTOR; INDOLEAMINE; METHAMPHETAMINE; METHYLPHENIDATE; NICOTINE; OPIATE; PROTEIN FOS; PSILOCYBINE;

ADDICTION; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN REGION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; EXPOSURE; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC LINKAGE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MACROMOLECULE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROCHEMISTRY; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR OCCUPANCY; REPORTER GENE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0345276623     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5149(03)00109-6     Document Type: Review

References (114)

1. Ernst M, Chefer S. Neuroimaging and substance abuse disorders in the year 2001. Curr Opin Psychiatry 2001;14:179-85.
2. Ernst M, London ED. Brain imaging studies of drug abuse: therapeutic implications. Semin Neurosci 1997;9:120-30.
3. Grant S, London ED, Newlin DB, et al. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA 1996;93:12040-5.
4. Bolla KI, Eldreth DA, London ED, et al. Orbitofrontal dysfunction in abstinent cocaine abusers performing a decision-making task. Neuroimage 2003;9:1085-94.
5. Bonson KR, Grant SJ, Contoreggi CS, et al. Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 2002;26:376-86.
6. Daglish MR, Weinstein A, Malizia AL, et al. Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. Am J Psychiatry 2001;158:1680-6.
7. Kilts CD, Schweitzer JB, Quinn CK, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry 2001;58:334-41.
8. Childress AR, Mozley PD, McElgin W, et al. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999;156:11-8.
9. Eden GF, Zeffiro T. Functional magnetic resonance imaging. In: Ernst M, Rumsey J, editors. Functional neuroimaging in child psychiatry. Cambridge (UK): Cambridge University Press; 2000. p. 45-58.
10. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-33.
11. Di Chiara G. From rats to humans and return: testing addiction hypotheses by combined PET imaging and self-reported measures of psychostimulant effects. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies'. Behav Pharmacol 2002;13:371-7.
12. Herscovitch P, Ernst M. Functional brain imaging with PET and SPECT. In: Ernst M, Rumsey J, editors. Functional neuroimaging in child psychiatry. Cambridge (UK): Cambridge University Press; 2000. p. 3-26.
13. Morris ED, Muzic Jr RF, Christian BC, et al. Modeling of receptor images in PET and SPECT. In: Ernst M, Rumsey J, editors. Functional neuroimaging in child psychiatry. Cambridge (UK): Cambridge University Press; 2000. p. 27-44.
14. Almeida P, Ribeiro MJ, Bottlaender M, et al. Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography. Eur J Nucl Med 1999;26:1580-8.
15. 2 receptors in the human brain. Eur J Pharmacol 1992;223:105-7.
16. 18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors. Synapse 1993;15:169-76.
17. Votaw JR, Ansari MS, Mason NS, et al. Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand. J Nucl Med 1995;36:1316-21.
18. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002;13:355-66.
19. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 1973;20:119-29.
20. Volkow ND, Wang GJ, Fowler JS, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999;65:PL7-12.
21. Sihver W, Nordberg A, Långström B, et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res 2000;113:143-57.
22. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999;13:337-45.
23. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-7.
24. 11C]WIN-35,428. J Neurosci 1998;18:8417-22.
25. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-82.
26. Volkow ND, Wang GJ, Fowler JS, et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J Pharmacol Exp Ther 1999;288:14-20.
27. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001;21:9414-8,
28. 18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000;295:1070-6.
29. Zubieta JK, Gorelick DA, Stauffer R, et al. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 1996;2:1225-9.
30. Chester JA, Cunningham CL. GABA(A) receptor modulation of the rewarding and aversive effects of ethanol. Alcohol 2002;26:131-43.
31. Mendez M, Leriche M, Calva JC. Acute ethanol administration differentially modulates mu opioid receptors in the rat meso-accumbens and mesocortical pathways. Brain Res Mol Brain Res 2001;94:148-56.
32. Hall FS, Sora I, Uhl GR. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) 2001;154:43-9.
33. Gordon AS, Yao L, Jiang Z, et al. Ethanol acts synergistically with a D2 dopamine agonist to cause translocation of protein kinase C. Mol Pharmacol 2001;59:153-60.
34. Tupala E, Hall H, Bergstrom K, et al. Dopamine D2/D3-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics. Mol Psychiatry 2001;6:261-7.
35. Valette H, Bottlaender M, Dolle F, et al. Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J Neurochem 2003;84:105-11.
36. 18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 2003;17(10):1331-3.
37. 123I]5-I-A-85380 SPECT. J Nucl Med 2000;41(9):1552-60.
38. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001;49:81-96.
39. 11C]raclopride in the human brain. Synapse 1994;16:255-62.
40. 2 receptors. J Pharmacol Exp Ther 1999;291:409-15.
41. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 1997;154:1209-13.
42. 11C]raclopride. Neuropsychopharmacology 1999;20:424-33.
43. Voruganti LN, Slomka P, Zabel P, et al. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001;107:173-7.
44. Dagher A, Bleicher C, Aston JA, et al. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse 2001;42:48-53.
45. 11]raclopride binding in unanesthetized monkeys. Synapse 2002;45:207-12.
46. McCann UD, Szabo Z, Scheffel U, et al. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352:1433-7.
47. Ricaurte GA, McCann UD, Szabo Z, et al. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett 2000;112-113:143-6.
48. 11C]flumazenil. Psychopharmacology (Berl) 1992; 107:180-5.
49. Lingford-Hughes AR, Acton PD, Gacinovic S, et al. Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy. Br J Psychiatry 1998;173:116-22.
50. 11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls. Psychiatry Res Neuroimag 1993;50:1-13.
51. Zubieta J, Greenwald MK, Lombardi U, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 2000;23:326-34.
52. Goethals I, Van De Wiele C, Audenaert K. Dopamine receptor imaging in alcohol dependency: should personality traits be taken into account? Eur J Nucl Med 2001;28:1585-8.
53. Ferguson RA, Goldberg DM. Genetic markers of alcohol abuse. Clin Chim Acta 1997;257:199-250.
54. Gilman S, Koeppe RA, Adams K, et al. Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. Ann Neurol 1996;40:163-71.
55. 123I]iomazenil. Am J Psychiatry 1998;155:1550-5.
56. 11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol 1998;44:326-33.
57. Little KY, Krolewski DM, Zhang L, et al. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003;160:47-55.
58. 123I]b-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smok ers and nonsmokers. Synapse 2001;41:275-84.
59. 123I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 2000;157:127-9.
60. Comer SD, Collins ED, Fischman MW. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology (Berl) 2001;154:28-37,
61. 3H]nicotine binding sites in human brain. J Neurochem 1988;50:1243-7.
62. Breslau N, Fenn N, Peterson EL. Early smoking initiation and nicotine dependence in a cohort of young adults. Drug Alcohol Depend 1993;33:129-37.
63. 18F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors. J Labelled Comp Radiopharm 1999;42:589-96.
64. 11C-raclopride and microPET. J Nucl Med 2002;43:1570-7.
65. 2 receptors in rat striatum by positron emission tomogmphy. Neuroreport 2000;11:743-8.
66. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998;18:419-27.
67. Fucile S, Barabino B, Palma E, et al. α 5 subunit forms functional α 3 β 4 α 5 nAChRs in transfected human cells. Neuroreport 1997;8:2433-6.
68. Kassiou M, Eberl S, Meikle SR, et al. In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nucl Med Biol 2001;28:165-75.
69. 8-THC. Pharmacol Biochem Behav 1991;40:503-7.
70. Tian X, Hsin LW, Webster EL, et al. The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type. Bioorg Med Chem Lett 2001;11:331-3.
71. Martarello L, Kilts CD, Ely T, et al. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl Med Biol 2001;28:187-95.
72. Uhl GR, Liu QR, Naiman D. Substance abuse vulnerability loci: converging genome scanning data. Trends Genet 2002;18:420-5.
73. True WR, Xian H, Scherrer JF, et al. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch Gen Psychiatry 1999;56:655-61.
74. Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998;55:967-72.
75. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 1997;9:482-97.
76. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend 1998;51:13-22.
77. Robbins TW, Everitt BJ. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 1996;6:228-36.
78. Uhl GR, Vandenbergh DJ, Rodriguez LA, et al. Dopaminergic genes and substance abuse. Adv Pharmacol 1998;42:1024-32.
79. Curtis D, Zhao JH, Sham PC. Comparison of GENE-HUNTER and MFLINK for analysis of COGA linkage data. Genet Epidemiol 1999;17(Suppl 1):S115-20.
80. Vandenbergh DJ, Rodriguez LA, Hivert E, et al. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene. Am J Med Genet 2000;96:678-83.
81. Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 1997;2:251-4.
82. Vandenbergh DJ, Rodriguez LA, Miller IT, et al. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 1997;74:439-42.
83. Horowitz R, Kotler M, Shufman E, et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 2000;96:599-603.
84. Jonsson EG, Nothen MM, Grunhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999;4:290-6.
85. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998;3:256-60.
86. Hilker R, Klein C, Hedrich K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 2002;323:50-4.
87. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998;42:211-21.
88. Martinez D, Gelernter J, Abi-Dargham A, et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene-is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001;24:553-60.
89. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997;19:591-611.
90. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993;11:995-1006.
91. Nestler EJ, Bergson CM, Gultart X, et al. Regulation of neural gene expression in opiate and cocaine addiction. NIDA Res Monogr 1993;125:92-116.
92. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000;25:515-32.
93. Emerson BM. Specificity of gene regulation. Cell 2002;109:267-70.
94. Ogbourne S, Antalis TM. Transcriptional control and the role of silencers in transcriptional regulation in eukaryotes. Biochem J 1998;331(Pt 1):1-14.
95. Guitart X, Thompson MA, Mirante CK, et al. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus-coeruleus. J Neurochem 1992;58:1168-71.
96. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001;2:119-28.
97. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci USA 2001;98:11042-6.
98. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999;68:821-61.
99. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609.
100. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002;35:605-23.
101. Bonci A, Williams JT. Increased probability of GABA release during withdrawal from morphine. J Neurosci 1997;17:796-803.
102. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63.
103. Unterwald EM, Cox BM, Kreek MJ, et al. Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse 1993;15:33-8.
104. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995;55:6126-32.
105. Hogemann D, Josephson L, Weissleder R, et al. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 2000;11:941-6.
106. Weissleder R, Reimer P, Lee AS, et al. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR Am J Roentgenol 1990;155:1161-7.
107. Mayerhofer R, Araki K, Szalay AA. Monitoring of spatial expression of firefly luciferase in transformed zebrafish. J Biolumin Chemilumin 1995;10:271-5.
108. Blasberg R. PET imaging of gene expression. Eur J Cancer 2002;38:2137-46.
109. Blasberg R. Imaging gene expression and endogenous molecular processes: molecular imaging. J Cereb Blood Flow Metab 2002;22:1157-64.
110. MacLaren DC, Toyokuni T, Cherry SR, et al. PET imaging of transgene expression. Biol Psychiatry 2000;48:337-48.
111. Gambhir SS, Barrio JR, Herschman HR, et al. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 1999;26:481-90.
112. Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 2002;16:336-51.
113. Cherry SR, Gambhir SS. Use of positron emission tomography in animal research. ILAR J 2001;42:219-32.
114. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002;16:352-61.